Literature DB >> 19424579

Deregulation of FOXO3A during prostate cancer progression.

Sanjeev Shukla1, Meenakshi Shukla, Gregory T Maclennan, Pingfu Fu, Sanjay Gupta.   

Abstract

Forkhead box transcription factor FOXO3A, an important regulator of cellular function, is thought to act as a tumor suppressor. We studied whether alterations in FOXO3A activity occur in prostate tumorigenesis. Our studies demonstrate that FOXO3A activity is negatively regulated by Akt/PKB through posttranslational modifications. In prostate cancer cells, Akt activation causes increased accumulation of FOXO3A and its binding chaperone protein 14-3-3 in the cytosol. Higher levels of FOXO3A in the cytosol correlated with phosphorylation at Ser253, which accounted for its nuclear exclusion. Dominant negative Akt approach in PC-3 cells increased FOXO3A accumulation in the nucleus, causing upregulation of the downstream target, MnSOD. Conversely, stable DU145-Akt over-expressing cells exhibited decreased FOXO3A levels in the nucleus. Similar findings were noted in prostate tumor specimens, in which marked cytoplasmic accumulation of FOXO3A and 14-3-3 in prostate tumors was observed with increasing Gleason grade, in contrast to exclusively nuclear accumulation in benign prostate cells. These findings correlate with decreased FOXO3A DNA binding activity along with down-modulation of FOXO3A transcriptional activity with increasing tumor grade. Our findings demonstrate that tumor associated alterations and redistribution of FOXO3A are frequent events in the etiology of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424579      PMCID: PMC2683383          DOI: 10.3892/ijo_00000291

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  35 in total

1.  Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155.

Authors:  X M Zhou; Y Liu; G Payne; R J Lutz; T Chittenden
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

Review 2.  Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors.

Authors:  K U Birkenkamp; P J Coffer
Journal:  Biochem Soc Trans       Date:  2003-02       Impact factor: 5.407

Review 3.  The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation.

Authors:  Lars P Van Der Heide; Marco F M Hoekman; Marten P Smidt
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

4.  The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation.

Authors:  Rebecca L Lynch; Bruce W Konicek; Ann M McNulty; Kimberly R Hanna; Jason E Lewis; Blake Lee Neubauer; Jeremy R Graff
Journal:  Mol Cancer Res       Date:  2005-03       Impact factor: 5.852

5.  Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile.

Authors:  Alvin Y Liu; Martine P Roudier; Lawrence D True
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

6.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage.

Authors:  M E McMenamin; P Soung; S Perera; I Kaplan; M Loda; W R Sellers
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

7.  IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a.

Authors:  Mickey C-T Hu; Dung-Fang Lee; Weiya Xia; Leonard S Golfman; Fu Ou-Yang; Jer-Yen Yang; Yiyu Zou; Shilai Bao; Norihisa Hanada; Hitomi Saso; Ryuji Kobayashi; Mien-Chie Hung
Journal:  Cell       Date:  2004-04-16       Impact factor: 41.582

8.  FOXO3a: a novel player in thyroid carcinogenesis?

Authors:  Stefan Karger; Carl Weidinger; Kerstin Krause; Sien-Yi Sheu; Thomas Aigner; Oliver Gimm; Kurt-Werner Schmid; Henning Dralle; Dagmar Fuhrer
Journal:  Endocr Relat Cancer       Date:  2008-10-09       Impact factor: 5.678

9.  NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.

Authors:  Ting-Lei Gu; Zuzana Tothova; Blanca Scheijen; James D Griffin; D Gary Gilliland; David W Sternberg
Journal:  Blood       Date:  2004-02-12       Impact factor: 22.113

10.  FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1.

Authors:  Walbert J Bakker; Montserrat Blázquez-Domingo; Andrea Kolbus; Janey Besooyen; Peter Steinlein; Hartmut Beug; Paul J Coffer; Bob Löwenberg; Marieke von Lindern; Thamar B van Dijk
Journal:  J Cell Biol       Date:  2004-01-19       Impact factor: 10.539

View more
  31 in total

1.  Negative regulation of the FOXO3a transcription factor by mTORC2 induces a pro-survival response following exposure to ultraviolet-B irradiation.

Authors:  Robert P Feehan; Lisa M Shantz
Journal:  Cell Signal       Date:  2016-04-04       Impact factor: 4.315

2.  FOXO3a: A Potential Target in Prostate Cancer.

Authors:  Sanjeev Shukla
Journal:  Austin J Urol       Date:  2014

3.  Expression and prognosis of FOXO3a and HIF-1α in nasopharyngeal carcinoma.

Authors:  Zhu Shou; Li Lin; Jia Liang; Jing-Li Li; Hong-Yan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-31       Impact factor: 4.553

4.  Characterization of squamous esophageal cells resistant to bile acids at acidic pH: implication for Barrett's esophagus pathogenesis.

Authors:  Aaron Goldman; Hwu Dau Rw Chen; Heather B Roesly; Kimberly A Hill; Margaret E Tome; Bohuslav Dvorak; Harris Bernstein; Katerina Dvorak
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-12-02       Impact factor: 4.052

5.  Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.

Authors:  Biswajyoti Sahu; Marko Laakso; Kristian Ovaska; Tuomas Mirtti; Johan Lundin; Antti Rannikko; Anna Sankila; Juha-Pekka Turunen; Mikael Lundin; Juho Konsti; Tiina Vesterinen; Stig Nordling; Olli Kallioniemi; Sampsa Hautaniemi; Olli A Jänne
Journal:  EMBO J       Date:  2011-09-13       Impact factor: 11.598

6.  Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies.

Authors:  Laura A Marlow; Christina A von Roemeling; Simon J Cooper; Yilin Zhang; Stephen D Rohl; Shilpi Arora; Irma M Gonzales; David O Azorsa; Honey V Reddi; Han W Tun; Heike R Döppler; Peter Storz; Robert C Smallridge; John A Copland
Journal:  J Cell Sci       Date:  2012-06-20       Impact factor: 5.285

Review 7.  Molecular signaling cascades involved in nonmelanoma skin carcinogenesis.

Authors:  Robert P Feehan; Lisa M Shantz
Journal:  Biochem J       Date:  2016-10-01       Impact factor: 3.857

Review 8.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

9.  Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1.

Authors:  Rajnee Kanwal; Mitali Pandey; Natarajan Bhaskaran; Gregory T Maclennan; Pingfu Fu; Lee E Ponsky; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2012-07-25       Impact factor: 4.784

10.  Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice.

Authors:  Sanjeev Shukla; Natarajan Bhaskaran; Gregory T Maclennan; Sanjay Gupta
Journal:  Prostate       Date:  2013-06-13       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.